Article

Autologous myoblast transplantation after myocardial infarction increases the inducibility of ventricular arrhythmias.

L'Institut du Thorax INSERM U533, Faculté de Médecine, 1 rue Gaston Veil, F-44035 Nantes cedex 1, France.
Cardiovascular Research (Impact Factor: 5.94). 03/2006; 69(2):348-58. DOI: 10.1016/j.cardiores.2005.10.003
Source: PubMed

ABSTRACT Small scale clinical trials suggested the feasibility and the efficacy of autologous myoblast transplantation to improve ventricular function after myocardial infarction. However, these trials were hampered by unexpected episodes of life-threatening ventricular tachyarrhythmias (VT). We investigated cardiac electrical stability after myoblast transplantation to the myocardium.
Seven days after coronary ligation, Wistar rats were randomized into 3 groups: a control group receiving no further treatment, a vehicle group injected with culture medium into the infarcted myocardium, and a myoblast group injected with autologous myoblasts. Holter monitoring did not discriminate the myoblast from the vehicle groups. Programmed Electrical Stimulation (PES) was performed to evaluate further a cardiac substrate for arrhythmia susceptibility. The occurrence of sustained VT during PES was similar in control and vehicle groups (5/17 and 4/19 rats, respectively; p=0.50). In contrast, 13/20 rats (65%) from the myoblast group showed at least one episode of sustained VT during PES (p<0.05 and p<0.005 versus control and vehicle groups). As a further control group, rats injected with autologous bone marrow mononuclear cells into the infarcted myocardium did not show increased susceptibility to PES.
In an infarcted rat model, myoblast transplantation but not bone marrow mononuclear cells or myocardial injection per se induces electrical ventricular instability. Because ventricular arrhythmias are life-threatening disorders, we suggest that such preclinical evaluation should be conducted for any new source of cells to be injected into the myocardium.

0 Bookmarks
 · 
51 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular disease is a major cause of morbidity and mortality throughout the world. Most cardiovascular diseases, such as ischemic heart disease and cardiomyopathy, are associated with loss of functional cardiomyocytes. Unfortunately, the heart has a limited regenerative capacity and is not able to replace these cardiomyocytes once lost. In recent years, stem cells have been put forward as a potential source for cardiac regeneration. Pre-clinical studies that use stem cell-derived cardiac cells show promising results. The mechanisms, though, are not well understood, results have been variable, sometimes transient in the long term, and often without a mechanistic explanation. There are still several major hurdles to be taken. Stem cell-derived cardiac cells should resemble original cardiac cell types and be able to integrate in the damaged heart. Integration requires administration of stem cell-derived cardiac cells at the right time using the right mode of delivery. Once delivered, transplanted cells need vascularization, electrophysiological coupling with the injured heart, and prevention of immunological rejection. Finally, stem cell therapy needs to be safe, reproducible, and affordable. In this review, we will give an introduction to the principles of stem cell based cardiac repair.
    Journal of Geriatric Cardiology 06/2013; 10(2):186-97.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diabetic cardiac autonomic neuropathy (DCAN) may cause fatal ventricular arrhythmias and increase mortality in diabetics. Mesenchymal stem cells (MSCs) can secrete various cytokines and growth factors exerting neurosupportive effects. In this study, we investigated the effect of MSC on DCAN in diabetic rats. Forty rats were divided into normal control, diabetes mellitus (DM) control, MSC treatment (6×10(6) MSCs via direct myocardial injection) and MSC-conditioned medium group (100μl via direct myocardial injection). Immunohistochemistry was used to measure choline acetyltransferase (ChAT, a marker for parasympathetic nerves) and tyrosine hydroxylase (TH, a marker for sympathetic nerves) positive nerve fibres in the ventricular myocardium. Heart rate variability and programmed electrical stimulation was used to assess the inducibility of ventricular arrhythmias in the animals. Two weeks after MSC treatment, the density of ChAT- and TH-positive nerve fibres in MSCs and MSC-conditioned medium group was higher than in DM control group (P<0.05 or P<0.01). The ChAT/TH ratio in MSC group was higher than in DM control group (0.37±0.014 vs. 0.27±0.020, P<0.01). The standard deviation of normal-to-normal R-R intervals in MSCs (5.13±0.69) and MSC-conditioned medium group (4.30±0.56) was higher than in DM control group (3.45±0.60, P<0.05). The inducibility of VAs in the MSC group was lower than in the DM control group. MSC therapy may promote cardiac nerve sprouting and increase the ratio of parasympathetic to sympathetic nerve fibres. It may also suppress the inducibility of ventricular arrhythmias in the diabetic rats.
    Heart Lung &amp Circulation 07/2013; · 1.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Skeletal myoblasts (SMs) transplantations are the focus of intense investigation due to their therapeutic potential for cardiac repair. Heart diseases are the main problem in humans worldwide, resulting very often in death of patients. Consequently, investigators sought methods which could improve myocardial function in patients with cardiac failure. Stem cells therapy belongs to one of the highly promising and the most realistic methods of treating myocardial infarction. Despite the fact that many cell types were transplanted into damaged myocardium, autologous skeletal myoblasts seem to be the most encouraging cell source for myocardial repair due to their myogenic and contractile phenotype, biochemical and functional similarities to cardiac cells, high proliferative capacity in vitro and resistance to ischemia. Moreover, engrafted myoblasts could repopulate post-infarction scar and improve cardiac function. Unfortunately, transplanted SMs do not functionally or electrically integrate with the host myocardium, which could also cause ventricular arrhythmias, therefore, the use of these cells still remains a subject of intensive studies aiming at improvement of this therapeutic method. In this paper we recapitulate the current state of knowledge concerning the use of skeletal myoblasts in the treatment of post-infarction scar tissue, and discuss the problems resulting from their applications.
    Journal of physiology and pharmacology: an official journal of the Polish Physiological Society 08/2013; 64(4):401-408. · 2.48 Impact Factor

Full-text (2 Sources)

View
13 Downloads
Available from
May 28, 2014